The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients
Abstract
Purpose: Standard therapy for glioblastoma (GBM) is temozolomide (TMZ) administration, initially concurrent with radiotherapy (RT), and subsequently as maintenance therapy. The radiologic images obtained in this setting can be difficult to interpret since they may show radiation-induced pseudoprogression (psPD) rather than disease progression. Methods: Patients with histologically confirmed GBM underwent radiotherapy plus continuous daily temozolomide (75 mg/m 2/d), followed by 12 maintenance temozolomide cycles (150 to 200 mg/m 2 for 5 days every 28 days) if magnetic resonance imaging (MRI) showed no enhancement suggesting a tumor; otherwise, chemotherapy was delivered until complete response or unequivocal progression. The first MRI scan was performed 1 month after completing combined chemoradiotherapy. Results: In 103 patients (mean age, 52 years [range 20 to 73 years]), total resection, subtotal resection, and biopsy were obtained in 51, 51, and 1 cases, respectively. MGMT promoter was methylated in 36 patients (35%) and unmethylated in 67 patients (65%). Lesion enlargement, evidenced at the first MRI scan in 50 of 103 patients, was subsequently classified as psPD in 32 patients and early disease progression in 18 patients. PsPD was recorded in 21 (91%) of 23 methylated MGMT promoter and 11 (41%) of 27 unmethylated MGMT promoter (P = .0002) patients. MGMT status (P = .001) and psPD detection (P = .045) significantly influenced survival. Conclusion: PsPD has a clinical impact on chemotherapy-treated GBM, as it may express the glioma killing effects of treatment and is significantly correlated with MGMT status. Improvement in the early recognition of psPD patterns and knowledge of mechanisms underlying this phenomenon are crucial to eliminating biases in evaluating the results of clinical trials and guaranteeing effective treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationResponse criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Therapeutic irradiation and brain injury
Sheline, G. E., Wara, W. M., & Smith, V. (1980) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(80)90175-3 · Cited by 965
Radiation‐induced dementia in patients cured of brain metastases
DeAngelis, L. M., Delattre, J.-Y., & Posner, J. B. (1989) · Neurology · doi:10.1212/wnl.39.6.789 · Cited by 941
Predicting lung cancer by detecting aberrant promoter methylation in sputum.
Palmisano, W. A., Divine, K. K., Saccomanno, G., Gilliland, F. D., Baylin, S. B., Herman, J. G., & Belinsky, S. A. (2000) · PubMed · Cited by 891
Stupp, R., Dietrich, P.-Y., Ostermann, S., Pica, A., Maillard, I. P., Maeder, P., Meuli, R. A., Janzer, R. C., Pizzolato, G., Miralbell, R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1375 · Cited by 856
Kumar, A. J., Leeds, N. E., Fuller, G. N., Van Tassel, P., Maor, M. H., Sawaya, R. E., & Levin, V. A. (2000) · Radiology · doi:10.1148/radiology.217.2.r00nv36377 · Cited by 669
Mirimanoff, R.-O., Gorlia, T., Mason, W., Van den Bent, M. J., Kortmann, R.-D., Fisher, B., Reni, M., Brandes, A. A., Curschmann, J., Villa, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5963 · Cited by 509
Self-citationImmediate post-radiotherapy changes in malignant glioma can mimic tumor progression
de Wit, M. C. Y., de Bruin, H. G., Eijkenboom, W., Sillevis Smitt, P. A. E., & van den Bent, M. J. (2004) · Neurology · doi:10.1212/01.wnl.0000133398.11870.9a · Cited by 357
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma
Chamberlain, M. C., Glantz, M. J., Chalmers, L., Van Horn, A., & Sloan, A. E. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9241-y · Cited by 343
van Engeland, M., Weijenberg, M. P., Roemen, G. M. J. M., Brink, M., de Bruïne, A. P., Goldbohm, R. A., van den Brandt, P. A., Baylin, S. B., de Goeij, A. F. P. M., & Herman, J. G. (2003) · PubMed · Cited by 299
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
Box, P. (2005) · Dkgest of the World Latest Medical Information · Cited by 299
Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas.
Castillo, M., Smith, J. K., Kwock, L., & Wilber, K. P. (2001) · PubMed Central · Cited by 267
Brandes, A. A., Tosoni, A., Cavallo, G., Bertorelle, R., Gioia, V, Franceschi, E., Biscuola, M., Blatt, V, Crinò, L., & Ermani, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603376 · Cited by 228
Self-citationBrandes, A. A., Tosoni, A., Cavallo, G., Reni, M., Franceschi, E., Bonaldi, L., Bertorelle, R., Gardiman, M., Ghimenton, C., Iuzzolino, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3891 · Cited by 196
Self-citationPerfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas
Catalaa, I., Henry, R. G., Dillon, W. P., Graves, E. E., McKnight, T. R., Lü, Y., Vigneron, D. B., & Nelson, S. J. (2006) · NMR in Biomedicine · doi:10.1002/nbm.1059 · Cited by 133
Brandes, A. A., Rigon, A., Zampieri, P., Ermani, M., Carollo, C., Altavilla, G., Turazzi, S., Chierichetti, F., & Fiorentino, M. V. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980115)82:2<362::aid-cncr17>3.0.co;2-x · Cited by 51
Self-citationTaal, W., Brandsma, D., de Bruin, H. G., Bromberg, J. E. C., Swaak‐Kragten, A. T., Eijkenboom, W. M. H., & van den Bent, M. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.2009 · Cited by 29
Cited by
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Self-citationWen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Self-citationGlioblastoma and Other Malignant Gliomas: A Clinical Review
Omuro, A. (2013) · JAMA · doi:10.1001/jama.2013.280319 · Cited by 2,301
Jacob, F., Salinas, R. D., Zhang, D. Y., Nguyen, P. T. T., Schnoll, J. G., Wong, S. Z. H., Thokala, R., Sheikh, S., Saxena, D., Prokop, S., et al. (2020) · Cell · doi:10.1016/j.cell.2019.11.036 · Cited by 1,149
Metadata
- Authors
- Brandes, A. A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., Bertorelle, R., Bartolini, S., Calbucci, F., Andreoli, A., Frezza, G., Leonardi, M., Spagnolli, F., & Ermani, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-05-01
- Volume
- 26
- Issue
- 13
- Pages
- 2192-2197
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2112014411
- Cited by
- 840
- References
- 19
- FWCI
- 25.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.